SEC Comment Letter 0000000000-23-013985 to Phio Pharmaceuticals Corp. (PHIO)
Phio Pharmaceuticals Corp.
Date: Dec. 21, 2023 · CIK: 0001533040 · Accession: 0000000000-23-013985
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-276146
Letter
United States securities and exchange commission logo December 21, 2023 Robert Bitterman President & CEO Phio Pharmaceuticals Corp. 257 Simarano Drive, Suite 101 Marlborough, MA 01752 Re:Phio Pharmaceuticals Corp. Registration Statement on Form S-1 Filed December 19, 2023 File No. 333-276146 Dear Robert Bitterman: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Daniel Crawford at 202-551-7767 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Brandon Kinnard, Esq.
Show Raw Text
United States securities and exchange commission logo
December 21, 2023
Robert Bitterman
President & CEO
Phio Pharmaceuticals Corp.
257 Simarano Drive, Suite 101
Marlborough, MA 01752
Re:Phio Pharmaceuticals Corp.
Registration Statement on Form S-1
Filed December 19, 2023
File No. 333-276146
Dear Robert Bitterman:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Daniel Crawford at 202-551-7767 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Brandon Kinnard, Esq.